STOCK TITAN
  1. Home
  2. Sec-filings
  3. JAGX
  4. [Form 4] Jaguar Health, Inc. Insider Trading Activity

Jaguar Health (JAGX) director granted 5,870 RSUs and stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Jaguar Health, Inc. director Anula Jayasuriya received equity awards consisting of 5,870 restricted stock units and stock options covering 5,870 shares of common stock, approved by the board on December 11, 2025 under the company’s 2014 Stock Incentive Plan.

Each restricted stock unit represents a right to receive one share and vests on December 11, 2026, while the options have a $1.44 exercise price, vest monthly over 12 months from the grant date, and expire on December 11, 2035. Following these grants, she beneficially owns 5,916 shares of common stock and 5,870 stock options, held directly.

Positive

  • None.

Negative

  • None.
Insider Jayasuriya Anula
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 5,870 $0.00 --
Grant/Award Common Stock 5,870 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 5,870 shares (Direct); Common Stock — 5,916 shares (Direct)
Footnotes (1)
  1. Granted pursuant to the issuer's 2014 Stock Incentive Plan. The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025. Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice. On May 23, 2024, the issuer effected a 60-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "2024 Reverse Stock Split"). Upon effectiveness of the 2024 Reverse Stock Split, every 60 shares of voting common stock was automatically converted into one share of voting common stock. On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "2025 Reverse Stock Split"). Upon effectiveness of the 2025 Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock. The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the reporting person continues to serve on the board of directors of the issuer.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Jayasuriya Anula
(Last) (First) (Middle)
C/O JAGUAR HEALTH, INC.
200 PINE ST., STE 400
(Street)
SAN FRANCISCO CA 94104
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Jaguar Health, Inc. [ JAGX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock(1) 12/11/2025(2)(3) A 5,870 A $0 5,916(4)(5) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)(1) $1.44 12/11/2025(2) A 5,870 (6) 12/11/2035 Common Stock 5,870 $0 5,870 D
Explanation of Responses:
1. Granted pursuant to the issuer's 2014 Stock Incentive Plan.
2. The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025.
3. Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice.
4. On May 23, 2024, the issuer effected a 60-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "2024 Reverse Stock Split"). Upon effectiveness of the 2024 Reverse Stock Split, every 60 shares of voting common stock was automatically converted into one share of voting common stock.
5. On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "2025 Reverse Stock Split"). Upon effectiveness of the 2025 Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock.
6. The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the reporting person continues to serve on the board of directors of the issuer.
/s/ Anula Jayasuriya 12/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider equity awards were reported for Jaguar Health (JAGX)?

The report shows that director Anula Jayasuriya received 5,870 restricted stock units and a stock option for 5,870 shares of Jaguar Health common stock, approved on December 11, 2025 under the company’s 2014 Stock Incentive Plan.

How many Jaguar Health (JAGX) restricted stock units did the director receive and when do they vest?

The director received 5,870 restricted stock units. Each unit represents a contingent right to receive one share of Jaguar Health voting common stock, and the units vest on December 11, 2026, with vested shares delivered on that vesting date.

What are the terms of the stock options granted to the Jaguar Health (JAGX) director?

The director was granted a stock option to buy 5,870 shares of common stock at an exercise price of $1.44 per share. The options vest ratably on a monthly basis over 12 months from the grant date and expire on December 11, 2035.

How many Jaguar Health (JAGX) shares and options does the director own after these transactions?

After the reported grants, the director beneficially owns 5,916 shares of common stock and 5,870 stock options, all held directly.

Under which plan were the Jaguar Health (JAGX) equity awards granted?

The restricted stock units and stock options were granted under Jaguar Health’s 2014 Stock Incentive Plan, as approved by the board of directors on December 11, 2025.

What recent reverse stock splits has Jaguar Health (JAGX) carried out?

Jaguar Health effected a 60-for-1 reverse stock split of its voting common stock on May 23, 2024, and a 25-for-1 reverse stock split on March 24, 2025, with each split automatically converting the specified number of old shares into one new share.